Advertisement
Screener

Harrow, Inc. (HROW) Business Acquisition, Pro Forma Revenue

Harrow, Inc. Business Acquisition, Pro Forma Revenue

Harrow, Inc. (HROW) reported Business Acquisition, Pro Forma Revenue of $1.56 million for the 3-month period ending 2015-03-31, per its 10-Q filed 2015-05-13.

Discontinued › Income Statement › Other Income

us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2015-11-12

  • Harrow, Inc. business acquisition, pro forma revenue for the quarter ending 2015-03-31 was $1.56M, a 2.36% increase year-over-year.
  • Harrow, Inc. business acquisition, pro forma revenue for the quarter ending 2014-12-31 was -$3.57M, a 609.74% decline year-over-year.
  • Harrow, Inc. business acquisition, pro forma revenue for the quarter ending 2014-09-30 was $1.85M, a 161.39% increase year-over-year.
  • Harrow, Inc. business acquisition, pro forma revenue for the quarter ending 2014-06-30 was $1.72M, a 131.22% increase year-over-year.
  • Harrow, Inc. business acquisition, pro forma revenue for fiscal 2014 was $2.28M, a 20.37% decline from fiscal 2013.
  • Harrow, Inc. business acquisition, pro forma revenue for fiscal 2013 was $2.87M.
Period endBusiness Acquisition, Pro Forma Revenue 3 monthBusiness Acquisition, Pro Forma Revenue 3 month as first filedBusiness Acquisition, Pro Forma Revenue 6 monthBusiness Acquisition, Pro Forma Revenue 6 month as first filedBusiness Acquisition, Pro Forma Revenue 9 monthBusiness Acquisition, Pro Forma Revenue 9 month as first filedBusiness Acquisition, Pro Forma Revenue 12 month
2015-03-31$1.56M
10-Q · filed 2015-05-13
-$2.00M
derived: sum of 2 quarters · filed 2015-05-13
-$150.32K
derived: sum of 3 quarters · filed 2015-11-12
$1.57M
derived: sum of 4 quarters · filed 2015-11-12
2014-12-31-$3.57M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12
-$1.71M
derived: sum of 2 quarters · filed 2015-11-12
$7.68K
derived: sum of 3 quarters · filed 2015-11-12
$2.28M
10-K · filed 2015-03-12
2014-09-30$1.85M
10-Q · filed 2015-11-12
$441.03K
10-Q · filed 2014-11-12
$3.57M
derived: sum of 2 quarters · filed 2015-11-12
$5.85M
10-Q · filed 2015-11-12
$1.73M
10-Q · filed 2014-11-12
$5.80M
derived: sum of 4 quarters · filed 2015-11-12
2014-06-30$1.72M
10-Q · filed 2015-08-12
$667.70K
10-Q · filed 2014-08-13
$3.25M
10-Q · filed 2015-08-12
$1.29M
10-Q · filed 2014-08-13
$3.95M
derived: sum of 3 quarters · filed 2015-08-12
$4.66M
derived: sum of 4 quarters · filed 2015-08-12
2014-03-31$1.53M
10-Q · filed 2015-05-13
$2.23M
derived: sum of 2 quarters · filed 2015-05-13
$2.94M
derived: sum of 3 quarters · filed 2015-05-13
$3.68M
derived: sum of 4 quarters · filed 2015-05-13
2013-12-31$699.63K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12
$1.41M
derived: sum of 2 quarters · filed 2015-03-12
$2.15M
derived: sum of 3 quarters · filed 2015-03-12
$2.87M
10-K · filed 2015-03-12
2013-09-30$708.89K
10-Q · filed 2014-11-12
$1.45M
derived: sum of 2 quarters · filed 2014-11-12
$2.17M
10-Q · filed 2014-11-12
2013-06-30$744.30K
10-Q · filed 2014-08-13
$1.45M
10-Q · filed 2014-08-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
Damora Therapeutics, Inc. (DMRA)$1.250B-6.10
OPKO HEALTH, INC. (OPK)United States$1.220B-15.59
LB PHARMACEUTICALS INC (LBRX)United States$1.220B-10.87
Avalyn Pharma Inc. (AVLN)United States$1.267B
First Tracks Biotherapeutics, Inc. (TRAX)United States$1.280B
Jaguar Health, Inc. (JAGX)United States$1.184B
Latigo Biotherapeutics, Inc. (LTGO)United States$1.176B
Bicara Therapeutics Inc. (BCAX)United States$1.309B-10.55
Tyra Biosciences, Inc. (TYRA)United States$1.337B-12.83
Kardigan, Inc. (KARD)United States$1.346B